Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 ...

Wednesday in The Lancet Microbe.The study focused on infections caused by Aspergillus fumigatus, a fungus that is ubiquitous ...

Olorofim, a novel antifungal agent, shows efficacy and tolerability in patients with invasive fungal diseases with limited ...

Fungal infections are becoming more drug-resistant and harder to treat. When will the FDA approve new antifungals?

A recent study published in the journal Biomedicines aimed to determine the antifungal tolerance of Candida auris (C. auris) to all three classes of antifungal drugs commonly used to treat ...

No new classes of antifungal drugs have become available during the last 20 years, according to a study in the journal Drugs, and only one new agent from a known antifungal class has been approved ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

Since the development of the first antifungals in the 1950s, four main antifungal classes have been indicated for the treatment of IFIs: polyenes, triazoles, echinocandins and pyrimidine analogues.

Scientists at King's have developed a new class of antifungal compounds that could offer a powerful weapon against the rising ...

Devastating health impacts Resistance is nowadays the rule rather than the exception for the four currently available antifungal classes, making it difficult - if not impossible – to treat many ...

"For decades, clinicians have relied on a handful of antifungal classes, with few mechanisms of action and significant limitations due to spectrum of activity, drug toxicities, or drug-drug ...